BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase HYALOFAST, a
BEDFORD, Mass. --(BUSINESS WIRE)--May 13, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative
BEDFORD, Mass. --(BUSINESS WIRE)--May 6, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that the Company will participate in
Total Revenue Increased 16% Year-over-Year Solid Bottom Line Performance with $0.31 Diluted EPS New Leadership Added to Accelerate Innovation and Expand Commercial Reach Announces $50 Million Share Repurchase Program BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc.
BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that its Board of Directors has
Seasoned commercial leader to oversee hybrid commercial organization and upcoming launch of Bone Repair Surgical Therapy in the U.S. BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday,
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative
Industry veteran brings extensive experience leading high-performing R&D groups BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 11, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its innovative
